Efficacy of flecainide acetate for atrial arrhythmias following coronary artery bypass grafting

The American Journal of Cardiology
S S WafaA J Camm

Abstract

The antiarrhythmic efficacy of intravenous flecainide and intravenous digoxin was assessed in 29 patients (26 men), aged 43 to 73 (63 +/- 7) years who developed atrial arrhythmias in the first 96 hours after coronary artery bypass grafting. Twenty-seven had atrial fibrillation and 2 had atrial flutter. Patients were entered into the study if the arrhythmia persisted for at least 15 minutes with a ventricular rate greater than 120 beats/min. Fifteen patients were randomized to flecainide (group 1) and 14 to digoxin (group 2). Flecainide was given as a bolus of 1 mg/kg over 10 minutes followed by an infusion of 1.5 mg/kg/hr for 1 hour and then 0.25 mg/kg/hr for the rest of the study period (24 hours). Digoxin was given as 3 bolus doses (0.5 mg followed after 6 and 12 hours by 0.25 mg). In both groups, 10 mg of verapamil was given intravenously after 45 minutes if the arrhythmia persisted with a mean ventricular rate greater than 100 beats/min. The antiarrhythmic efficacy was assessed by 24-hour Holter monitoring and frequent 15-second rhythm strips. Within 45 minutes control of arrhythmia, which was maintained for the rest of the study period, was achieved in 10 of 15 patients in group 1 and 2 of 14 in group 2 (p less than 0.01)....Continue Reading

References

Mar 1, 1987·The American Journal of Cardiology·I G CrozierL Levy
Feb 1, 1985·Australian and New Zealand Journal of Medicine·T P GavaghanJ J Morgan
May 1, 1985·Journal of the American College of Cardiology·F L Meijler
Feb 27, 1984·The American Journal of Cardiology·N A EstesJ N Ruskin
Feb 1, 1983·The American Journal of Cardiology·V LegrandH E Kulbertus

❮ Previous
Next ❯

Citations

Jun 1, 1991·Cardiovascular Drugs and Therapy·R Bolognesi
Aug 29, 1998·Intensive Care Medicine·K H StrickerJ Fuhrer
Jun 5, 2012·Heart and Vessels·Hiroyuki NishiYoshiki Sawa
Feb 24, 2005·The Japanese Journal of Thoracic and Cardiovascular Surgery : Official Publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai Zasshi·Kazuyuki KuriuMakoto Sunamori
Oct 31, 2006·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Joel DunningUNKNOWN EACTS Audit and Guidelines Committee
Nov 1, 1996·The American Journal of Cardiology·M R GoldR W DeSanctis
Sep 1, 1991·British Journal of Clinical Pharmacology·K S Channer
Dec 30, 2008·Cardiology Clinics·Krit Jongnarangsin, Hakan Oral
Dec 7, 2007·The Medical Clinics of North America·Krit Jongnarangsin, Hakan Oral
Aug 20, 1992·The American Journal of Cardiology·J F LeclercqR Slama
Jul 8, 2015·Journal of Thrombosis and Haemostasis : JTH·A BessissowP Alonso-Coello
Sep 24, 2004·Current Opinion in Critical Care·Hans KnotzerWalter R Hasibeder
Sep 24, 2019·The Cochrane Database of Systematic Reviews·Hermann BlessbergerClemens Steinwender
Feb 27, 2013·The Cochrane Database of Systematic Reviews·Kyle A ArsenaultRichard P Whitlock
Sep 19, 2014·The Cochrane Database of Systematic Reviews·Hermann BlessbergerClemens Steinwender

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.